FDA adds new warning on Tysabri label, but says benefits still outweigh dangers.
Posted: 2010-02-04 19:00:00
More from this author:
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Multiple Sclerosis Relapses and Severe Disability
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Stress, Fear, Anxiety and MS
From the Web > About.com Multiple Sclerosis: Most Popular Article
From the Web > About.com Multiple Sclerosis: Most Popular Article
Puusepp's sign—Clinical significance of a forgotten pyramidal sign
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Related Articles:
Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis
From the Web > MedWorm: Multiple Sclerosis
An algorithm for automatic segmentation and classification of magnetic resonance brain images
From the Web > MedWorm: Multiple Sclerosis
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation
From the Web > Multiple Sclerosis RSS feed -- OnlineFirst Article
